HI
NTLA icon

Harbour Investments’s Intellia Therapeutics NTLA Stock Holding History

Harbour Investments’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127K Buy
7,534
+185
+3% +$2.59K ﹤0.01% 1858
2026
Q1 		$94.2K Buy
7,349
+524
+8% +$6.67K ﹤0.01% 1982
2025
Q4 		$61.4K Buy
6,825
+269
+4% +$3.7K ﹤0.01% 1868
2025
Q3 		$113K Sell
6,556
-77
-1% -$948 ﹤0.01% 1527
2025
Q2 		$62.2K Buy
6,633
+1,419
+27% +$11.7K ﹤0.01% 1710
2025
Q1 		$37.1K Buy
5,214
+2,264
+77% +$22.9K ﹤0.01% 1919
2024
Q4 		$34.4K Buy
2,950
+784
+36% +$12.2K ﹤0.01% 1893
2024
Q3 		$44.5K Buy
2,166
+455
+27% +$10.5K ﹤0.01% 1725
2024
Q2 		$38.3K Buy
1,711
+86
+5% +$2.05K ﹤0.01% 1683
2024
Q1 		$44.7K Buy
1,625
+861
+113% +$23.9K ﹤0.01% 1575
2023
Q4 		$23.3K Buy
+764
New +$22K ﹤0.01% 1806
2021
Q4 		$5K Sell
43
-19
-31% -$2.38K ﹤0.01% 2183
2021
Q3 		$8K Buy
62
+9
+17% +$1.36K ﹤0.01% 2778
2021
Q2 		$9K Buy
53
+21
+66% +$1.64K ﹤0.01% 2801
2021
Q1 		$3K Buy
+32
New +$2.15K ﹤0.01% 3107

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Harbour Investments's NTLA Position: Q2 2026 in Review

Harbour Investments increased its Intellia Therapeutics (NTLA) stake by 2.5% in Q2 2026, buying an estimated $2.59K and bringing the position to 7,534 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #1858.

Harbour Investments first reported a position in NTLA in Q1 2021 and has held it in 15 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Harbour Investments held 7,534 shares of Intellia Therapeutics worth $127K as of Q2 2026.
  • Harbour Investments bought 185 Intellia Therapeutics shares in Q2 2026, an estimated $2.59K.
  • Intellia Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #1858 holding.
  • Harbour Investments first reported a position in Intellia Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.